Elevated RDW and increase in RDW during hospitalization linked to increased mortality risk
WEDNESDAY, Sept. 23, 2020 (HealthDay News) — For patients with COVID-19, elevated red blood cell distribution width (RDW) is associated with increased mortality risk, according to a study published online Sept. 23 in JAMA Network Open.
Brody H. Foy, D.Phil., from Massachusetts General Hospital in Boston, and colleagues examined the association between mortality risk and elevated RDW at hospital admission and during hospitalization in 1,641 patients with COVID-19 admitted to one of four hospitals.
The researchers found that among patients of all ages, elevated RDW (>14.5 percent) was associated with increased mortality risk. For the entire cohort, the relative risk (RR) was 2.73, with a mortality rate of 11 and 31 percent for those with normal and elevated RDW, respectively. The RRs were 5.25 for patients younger than 50 years, 2.90 for those aged 50 to 59 years, 3.96 for those aged 60 to 69 years, 1.45 for those aged 70 to 79 years, and 1.59 for those aged 80 years and older. In models adjusted for age, D-dimer level, absolute lymphocyte count, and common comorbidities such as diabetes and hypertension, RDW was associated with mortality risk (hazard ratio, 1.09 per 0.5 percent RDW increase and 2.01 for an RDW >14.5 versus ≤14.5 percent). Mortality was higher for patients whose RDW increased during hospitalization compared with those whose RDW did not change.
“Such discoveries could point to new treatment strategies or identify better markers of disease severity,” a coauthor said in a statement.
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2
Ultra-Endurance Running Accelerates Red Blood Cell Aging
Maternal Anemia, Erythrocytosis Linked to Neonatal Morbidity and Mortality
Recommendations Developed for Diagnosing Light Chain Amyloidosis
IV Iron Dextran Cost-Effective for Managing Iron-Deficiency Anemia
Liberalized Diet Not a Safe Alternative to Neutropenic Diet in Adults Being Treated for Acute Leukemia
Exa-Cel Gene Therapy Improves Quality of Life in Severe Sickle Cell Disease
Age, Disease Duration Are Predictors of CKD After Stem Cell Transplant